Cognition Therapeutics

Cognition Therapeutics

Cognition Therapeutics was founded in 2007, based on research into oligomer-pathway biology conducted by its scientific founders out of the University of Pittsburgh. The company operates as a publicly traded clinical-stage biopharmaceutical firm, not a family office, and its capital comes from equity markets and grant funding rather than a single family's wealth pool. Lisa Ricciardi took the CEO post in 2023, bringing a commercial-stage pedigree from roles at Turning Point Therapeutics and Array BioPharma. The company's therapeutic focus rests entirely on sigma-2 receptor modulation. Its lead drug candidate, CT1812, is an orally delivered small molecule designed to displace toxic amyloid-beta oligomers from synaptic receptor sites. Two Phase 2 trials have read out: the SHINE study in mild-to-moderate Alzheimer's, which showed a statistically significant cognitive benefit in a pre-specified subgroup with lower baseline plasma p-tau217, and the SHIMMER study in dementia with Lewy bodies, which demonstrated a significant safety signal but missed its primary cognitive endpoint. Both trials inform an upcoming Phase 2/3 program that Cognition plans to advance with a strategic partner. The company raised roughly $45 million in its 2021 IPO and subsequently drew grant support from the National Institute on Aging for more than $80 million in total non-dilutive funding. Team size is not publicly fixed but the firm operates a lean clinical-development model, outsourcing manufacturing and large-trial execution. There are no known adjacent vehicles or philanthropic arms. As of early 2025, the board added neuroscience drug-development veteran Anthony Caggiano, signaling a build toward late-stage regulatory capability. Structurally, Cognition Therapeutics is an unusual bet among neurodegenerative drug companies: it bypasses the now-crowded anti-amyloid antibody space entirely, targeting a receptor complex that sits upstream of multiple misfolded protein cascades. Its single-molecule, multiple-indication thesis — Alzheimer's, Lewy body dementia, and potentially dry age-related macular degeneration — is a cost-efficient binary that will likely be resolved by a partnership or acquisition before a full Phase 3 registration program is independently completed.